Bcl-2 is an oncoprotein that plays a critical role in inhibiting apoptotic cell death in the mitochondria-dependent pathway in cancer chemotherapy. As a strategy for blocking Bcl-2 for enhancement of the chemotherapeutic effect, antisense Bcl-2 (AS Bcl-2; G3139, oblimersen sodium, Genasense) has shown promise, and there are several ongoing clinical studies with hematological malignancies as well as solid tumors. Although several preclinical and clinical studies have shown the therapeutic efficacy of Bcl-2 in combination with an anticancer drug as a chemosensitizer, in clinical trials the downregulation of Bcl-2 has not been observed with a high frequency in tumor cells. Nevertheless, previous studies showed nonantisense effects such as production of reactive oxygen species and immunostimulatory action through cytosine-phosphate-guanosine-motif in the antisense oligodeoxynucleotides. Further, Bcl-2 is able to inhibit Beclin 1-dependent autophagic cell death, which is a nonapoptotic cell death. The current status and future directions of AS Bcl-2 and the potential mechanisms for multiple roles that Bcl-2 has in cancer therapy are reviewed.
Introduction
Bcl-2 is an oncoprotein, which was originally identified as the t(14;18) chromosomal translocation found in the majority of human follicular lymphomas. 1 It has been established that Bcl-2 plays a critical role in inhibiting apoptotic cell death. 2 Overexpression of Bcl-2 is associated with drug resistance, [3] [4] [5] and its transfection into cancer cells produces a drug resistance phenotype. 6, 7 The overexpression of Bcl-2 has been noted in various types of cancers such as hematological malignancies as well as in solid tumors. [8] [9] [10] As the overexpression of Bcl-2 produces a drug resistance phenotype that is resistant to apoptosis, the downregulation of Bcl-2 can enhance its chemotherapeutic effect when used in combination with an anticancer drug. 11 Bcl-2 confers a mitochondria-dependent apoptosis pathway, which is mediated by mitochondrial dysfunction. 12 Mitochondria have a central role as the garden of cell death, which regulates mitochondrial membrane potential (DeltaPsim) and mitochondrial outer membrane permeabilization (MOMP). 13, 14 Chemotherapeutic druginduced decrease in DeltaPsim leads to an increase in MOMP, resulting in the release of proapoptotic small molecules such as cytochrome c, second mitochondriaderived activator of caspase/direct inhibitor of apoptosisbinding protein with low pl (Smac/DIABLO) and apoptosis-inducing factor (AIF) through permeability transition pores in caspase-dependent and -independent pathways. 15, 16 Chemotherapeutic drug-induced MOMP promotes Bax/Bak oligomerization and their translocation to mitochondrial membranes, which induces the release of proapoptotic molecules from the mitochondria. 17 Bcl-2 inhibits the loss of DeltaPsim and subsequent increase in MOMP, thereby blocking the release of proapoptotic molecules.
Antisense Bcl-2 (G3139, oblimersen sodium, Genasense, Genta, Berkeley Heights, NJ) is an 18-mer phosphorothioate oligonucleotide designed to bind to the first six codons of the human Bcl-2 mRNA. 11, 18 Several preclinical and clinical studies showed that the combination treatment with antisense Bcl-2 (AS Bcl-2) and an anticancer drug increased the chemotherapeutic effect in various types of cancers. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Nevertheless, despite the fact that in some clinical trials combination therapy with AS Bcl-2 and anticancer drug increased the response rate for metastatic melanoma and chronic lymphocytic lymphoma (CLL), 30 ,31 downregulation of Bcl-2 was observed in 10-50% of tumor samples. 32 The low frequency of downregulation of Bcl-2 in clinical samples does not necessarily diminish its therapeutic value against cancer cells. Rather, the increased therapeutic effect can be explained by the antisense effect of the downregulation of Bcl-2 enhancing the mitochondriadependent apoptosis pathway. Also, conceivably, the nonantisense effect such as an immunostimulatory action through a cytosine-phosphate-guanosine (CpG)-motif might contribute to the antitumor effects. 20, 33, 34 In this review, the current status and future directions of AS Bcl-2 therapy, and the potential mechanisms including antisense and nonantisense effects by which AS Bcl-2 enhances the chemotherapeutic effect for multiple roles of Bcl-2 are discussed.
Potential mechanisms of AS Bcl-2 for multiple roles of Bcl-2 Antisense effect Apoptotic cell death. As Bcl-2 plays a critical role in inhibiting chemotherapeutic agent-induced apoptosis, the downregulation of Bcl-2 by AS Bcl-2 enhances the mitochondria-dependent apoptosis pathway leading to cell death. In preclinical studies, the treatment with AS Bcl-2 in combination with an anticancer drug decreased Bcl-2, together with the increase in Bax and poly(ADPribose) polymerase (PARP) leading to apoptosis. 20, 21 The downregulation of Bcl-2 by AS Bcl-2 facilitates the release of proapoptotic small molecules from the mitochondria through the loss of DeltaPsim and increase in MOMP, resulting in activation of caspase-dependent and -independent pathways. The released cytochrome c interacts with Apaf-1, and this complex recruits caspase-9 in the presence of dATP, to form a holoenzyme called the apoptosome. The apoptosome then catalytically activates effector caspase-3 by cleavage, resulting in wide-spread proteolysis of the substrates such as PARP and inhibitor of caspase-activated DNase leading to DNA fragmentation in apoptosis. 15 Smac/DIABLO, the second small molecule released from mitochondria, inhibits inhibitors of apoptosis proteins (IAPs) such as c-IAP1, c-IAP2 35 and survivin, 36 resulting in the activation of caspase-9. Smac/DIABLO also directly promotes the activation of caspase-3. 37 AIF, the third small molecule released from mitochondria, directly induces fragmentation of high molecular weight DNA, producing nuclear condensation leading to apoptotic cell death. 38 Thus, downregulation of Bcl-2 is able to induce proapoptotic small molecules, which enhance chemotherapeutic drug-induced apoptotic cell death.
In another aspect of mitochondria associated with cell death, mitochondria are involved in the protection from oxidative stress. Bcl-2 exerts an antioxidant action whereby the cells are protected from oxidative stress to maintain cellular homeostasis. The antioxidant action of Bcl-2 is also involved in the inhibition of anticancer drug-induced DNA damage and drug resistance in cancer cells. 39 The downregulation of Bcl-2 by AS Bcl-2 decreases the protection of antioxidant action in mitochondria, resulting in the production of reactive oxygen species (ROS) for cellular damage. In fact, a previous study showed that ROS in PC3 and DU145 prostate cancer cells was produced by AS Bcl-2, which contributed to its induction of an antitumor effect. 40, 41 Another report indicated that the enhanced antitumor effect by 5-fluorouracil with AS Bcl-2 was less than that of other anticancer drugs such as cisplatin and paclitaxel in gastric cancer cells. 21 Nonapoptotic cell death. Recent advances in the mechanisms of anticancer drug-induced cell death have concluded that apoptotic cell death as well as nonapoptotic cell death such as autophagic cell death is involved in the overall tumor response resulting in cell death. 15, 42 Autophagic cell death is considered to be an intracellular degradation of organelles by lysosomes through the formation of autophagosomes. 43 Recent studies indicate that autophagy plays a dual role in cellular homeostasis. When nutrition is depleted, cell survival is attributed to autophagy by producing ATP energy from the degradation of intracellular organelles. 44 In contrast, autophagy in the absence of nutrient depletion leads to cell death. Beclin 1 is an autophagy-inducible gene in mammalian cells, which was initially discovered as a Bcl-2 interacting protein. 45, 46 Beclin 1 suppresses tumorigenesis as a tumor suppressor gene, which is deleted by 40-75% in sporadic breast and ovarian cancers. 46 A recent study showed that Bcl-2 proteins inhibited Beclin 1-dependent autophagy. 47 Bcl-2 not only functions as an antiapoptotic protein, but also as an antiautophagic protein via its inhibitory interaction with Beclin 1. This antiautophagic function of Bcl-2 helps maintain autophagy at levels that are compatible with cell survival, rather than cell death. Wildtype Bcl-2 proteins, but not Beclin 1 binding-defective mutants of Bcl-2, inhibit Beclin 1-dependent autophagy in mammalian cells. In such situations, the inhibition of Bcl-2 by AS Bcl-2 facilitates the induction of Beclin 1-dependent autophagy in cancer cells. In fact, a previous study reported that the treatment of HL-60 leukemic cells with AS Bcl-2 induced autophagic cell death. 48 It remains to be established how much the induction of autophagic cell death by AS Bcl-2 or in combination with an anticancer drug can contribute to antitumor effects in vivo and in clinical situations.
Other antisense effect. As Bcl-2 is a target of nuclear factor-kappaB (NF-kB), which is involved in cancer metastasis and angiogenesis, 49 ,50 the activated Bcl-2 induces vascular endothelial growth factor (VEGF) expression in endothelial cells, resulting in the promotion of tumor angiogenesis. 51 The downregulation of Bcl-2 by AS Bcl-2 inhibits the activity of NF-kB and decreases the expression of VEGF, thereby inhibiting tumor angiogenesis. Given that Bcl-2 has a crucial role in the formation of metastatic lesions, 50 the downregulation of Bcl-2 by AS Bcl-2 in tumor cells contributes to a decrease of metastatic potential. Further, the indirect inhibition of VEGF by AS Bcl-2 may be viewed as an immunostimulatory function.
As VEGF plays a critical role in producing immature myeloid cells (iMCs) from bone marrow that confer immune evasion in tumor cells, 52 the inhibition by AS Bcl-2 may modulate the cancer immunosuppressive network.
Nonantisense effect Immunostimulatory effect. AS Bcl-2, which is considered to exert an immunostimulatory action, has two CpG-motifs in the antisense oligodeoxynucleotides (ODNs). 20, 33, 34, 53 In the history of antitumor effects of CpG ODNs, the first indication that CpG-DNA possessed an immunostimulatory effect was observed in Coley's toxin in 1893. 54 Clinical remission was observed in 45% of 849 cancer patients when treated with a bacterial lysate. The active component of bacterial DNA was shown to be responsible for the immunostimulatory effects. 55 The immunostimulatory activity of bacterial DNA was conferred to a specific base-pair sequence, and synthetic ODNs containing these same sequences were identified as unmethylated CpG dinucleotides. 56 Given that a specific CpG-motif was recognized by toll-like receptor 9 (TLR9), the effector mechanism mediated by TLR9 was established. 57 The activation of plasmacytoid dendritic cells (pDCs) and B cells by CpG ODNs through TLR9 in an innate immune response produces type I interferons (IFN) such as IFN-a and -b, several cytokines such as interleukin (IL)-6 and IL-12, and increased expression of costimulatory molecules and major histocomaptibility complex class II, all of which can be connected to the activation of natural killer (NK), CD4 þ and CD8 þ T cells in adaptive immune responses. 58 In the case of AS Bcl-2 ODNs, previous studies showed that treatment with AS Bcl-2 produced splenomegaly and an increase in IL-12 in severe combined immunodeficient 33 and in nude mice. 20 Further, the abrogation of the immunostimulatory action by methylated cytosine in the CpG-motif did not decrease the antitumor effect of AS Bcl-2 on melanoma and breast xenografts transplanted into these mice, suggesting that the antitumor effect was independent of the methylated CpG-motif.
In our previous study in a nude mouse model, treatment with AS Bcl-2 induced splenomegaly and increase in IL-12, which was abrogated by the methylation of cytosine in CpG ODNs of AS Bcl-2. 20 Further, in our recent study, although there was no increase of IFN, the expression of costimulatory molecules such as CD80 and CD86 in the pDCs and B cells derived from splenomegaly was increased after the treatment with AS Bcl-2 ODNs. When untreated, CD80 was constitutively overexpressed compared to CD86, whereas when treated the expression of CD86 was greater than CD80 (Figures 1  and 2a) . Further, the expression of CD83, which is the maturation marker of pDCs, was increased after the treatment with AS Bcl-2, whereas there was no change in the expression of CD40. In addition, and as expected, the expression of CD27, which is the marker of memory B cells, was increased after the treatment with AS Bcl-2 ( Figure 2b ). The changes in the increased expression of CD80, CD86 and CD27 in response to AS Bcl-2 ODNs were similar to that of CpG ODNs in previous reports. 59 The CpG ODNs were classified into three types: 60 CpG-A (D-type): high IFN-a production in pDCs but lack of Bcell stimulation; CpG-B (K-type): low at inducing IFN-a, but strong B-cell stimulation; CpG-C: high IFN-a production in pDCs and strong B-cell stimulation. It is likely that the differential effect of pDCs and B cells on immunostimulatory action is dependent on the structural backbone and poly-G tails. Given that AS Bcl-2 has the structural backbone of phosphorothioate oligonucleotides, it is close to type B or C ODNs in terms of their function.
A hypothetical model of the immunostimulatory response by AS Bcl-2 is summarized in Figure 3 . The AS Bcl-2 ODNs are recognized by TLR9 in the pDCs and B cells in the marginal zone of the spleen. The pDCs are activated and matured during the increase in expression of costimulatory molecules. They produce IL-12, resulting in polarization of Th1 for tumor-specific immune responses by T-cell priming. The reason for the lack of secretion of IFN-a may be owing to the inhibitory effect by IL-12 in the pDCs. 61 Although IL-10 regulated pDC activation in the tumor microenvironment, it did not inhibit the subsequent T-cell-priming ability of pDCs activated by AS Bcl-2 ODNs. The activation of CD4 þ T cells produces IFN-g, which activates CD8 þ T cells for an adaptive immune response. The activated B cells produce IL-12 aided by the presence of CD40L and CD4 þ T cells, which activate NK cells for producing IFN-a connected with the activation of CD8 þ T cells. The activation of B cells promotes the differentiation to plasma cells, and produces tumor antigen-specific antibodies with IgM and IgG, which activate CD4 þ T cells. A recent phase II clinical trial of G3139 in combination with dexamethasone and thalidomide for relapsed multiple myeloma patients showed that responding patients had a significant increase in polyclonal IgM, indicating the activation of an innate immune system. 34 In the immunostimulatory action of AS Bcl-2 to increase the chemotherapeutic effect, it should be noted that the immune activation by the CpG-motif in the AS Bcl-2 ODNs through TLR9 may stimulate proinflammatory responses to immune cells. Unmethylated CpG-motif can stimulate TLR9 expressed on subsets of B cells and lymphoid dendritic cells (DC) and this can induce the production of polyclonal antibodies such as IgM and the maturation of the DC with secretion of multiple cytokines including IL-6 and IFN-a. 53, 56, 58 This is because the immune cells such as antigen-presenting cells (APCs) are shifted in anti-inflammatory situations by IL-10, transforming growth factor-b and prostaglandin E 2 , which are induced by tumor-associated macrophages and tumorderived soluble factors (TDSFs) in the tumor microenvironment. 62 The immature pDCs are recruited to the tumor site from the bone marrow through stromal-derived factor-1 (SDF-1)/CXCR4 interaction, where they are biochemically and functionally modulated as tumorassociated immature pDCs. This has been attributed to the inhibition of DC and T-cell activation. 63 Nevertheless, the activation of immature pDCs by AS Bcl-2 and proinflammatory response promote tumor immunity in the tumor antigen-presenting pDCs. Induction of massive cell death in combination with AS Bcl-2 and anticancer drug can release tumor antigen that facilitates the immune activation by pDCs for crosspriming of T cell, which is stimulated by CpG in the AS Bcl-2 ODNs through TLR9. Indeed, apoptotic cancer cells release antigen, enhancing the crosspriming of T cells. 64 The other potential aspect for immunostimulatory action by AS Bcl-2 is the targeting of immature myeloid cells, which include immature DCs and immature pDCs. 65 The iMCs are derived from the bone marrow, and are induced by TDSFs such as VEGF and SDF-1 to play a critical role in exerting immune evasion in primary tumor sites extending to the secondary lymph nodes and peripheral vessels of the immunosuppressive network. 52, 66 These iMCs are primarily recruited to tumor sites to modulate immunosuppressive functions, where the iMCs are resistant to apoptosis by inducing Bcl-2. The treatment with AS Bcl-2 downregulates the expression of Bcl-2 in iMCs, making the iMCs susceptible to cell death, and decreasing its immunosuppressive function. Further studies will be required to elucidate how the immunostimulatory action of the CpG-motif in the AS Bcl-2 can be utilized for antitumor effects in in vivo and clinical situations.
Other nonantisense effect. Previous studies have reported that treatment with AS Bcl-2 induces various cellular responses, such as an increase in the IFN cascade, a decrease in protein kinase C (PKC)a and an increase in p21 waf1 , all of which are associated with the growth inhibition of cancer cells. 67 The increased IFN cascade may be owing to the effect of CpG-motif, which can lead to the decreased PKCa and increased p21 waf1 resulting in growth inhibition of cancer cells. It is not clear whether these findings are the consequences of indirect effects of AS Bcl-2 ODNs or a direct antisense effect. Nevertheless, it is likely that these previous findings are explained not only by an antisense effect but also by nonantisense effects of AS Bcl-2 ODNs.
These potential antisense and nonantisense effects of AS Bcl-2 in the multiple roles of Bcl-2 are summarized in Figure 4 . 
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Clinical applications of AS Bcl-2 for cancer chemotherapy Randomized clinical trials. Based on several phase I/II clinical trials of AS Bcl-2, which were conducted to assess its safety, tolerance and therapeutic efficacy 23-29 on hematological malignancies and solid tumors, the first randomized phase III trial has been conducted for metastatic melanoma. The results were compared with dacarbazine and AS Bcl-2/dacarbazine. 30 Although the primary end point of overall survival was not significantly different, overall response rate, complete response and progression-free survival were significantly superior with oblimersen sodium/dacarbazine than with dacarbazine alone. The initial application as a new drug to the Food and Drug Administration was not approved because of insufficient data for demonstrating the survival benefit of oblimersen sodium. However, a more recent analysis of overall survival showed close to a significant difference in the two groups. 30 The oblimersen sodium is being applied for approval by the European Medicines Agency. The second phase III randomized trial for relapsed multiple myeloma with dexamethasone versus oblimersen sodium/ dexamethasone showed that there was no significant difference in time to tumor progression between the two groups. In contrast, the third randomized phase III trial for chronic lymphocytic leukemia (CLL) with fludarabine/ cyclophosphamide versus oblimersen sodium/fludarabine/ cyclophosphamide showed that the primary end point of complete response was significantly superior in the treatment with oblimersen sodium/fludarabine/cyclophosphamide over that of fludarabine/cyclophosphamide. 31 Further, nodal partial response in the treatment with oblimersen sodium/fludarabine/cyclophosphamide was also significantly superior to fludarabine/cyclophosphamide. Based on these findings in CLL, oblimersen sodium is being processed as a new drug application. The fourth phase III randomized trial for non-small cell lung cancer (NSCLC) with docetaxel versus oblimersen sodium/ docetaxel has been completed, in which the end point was overall survival. The data will be available in the first half of 2006. In the ongoing randomized trials, a phase III trial for acute myeloid leukemia with daunorubicin/ cytosine arabinoside versus oblimersen sodium/daunorubicin/cytosine arabinoside has been enrolled in the Cancer and Leukemia Group B. The other phase II randomized trial for hormone-refractory prostate cancer (HRPC) with docetaxel versus oblimersen sodium/docetaxel has been enrolled in the European Organization for Research and Treatment of Cancer (EORTC) ( Table 1) .
Nonrandomized clinical trials. The phase I/II clinical trials for solid tumors such as gastrointestinal and breast cancers have been reported (Table 2) . A phase I trial for advanced, esophageal, gastric-esophageal junction and gastric cancers with oblimersen sodium/cisplatin/5-fluorouracil showed one complete response and two partial responses in nine patients. 68 A phase I trial for metastatic colorectal cancer with oblimersen sodium/oxaliplatin/ Effects of antisense Bcl-2 on multiple roles of Bcl-2 R Kim et al 5-fluorouracil/leucovorin (FOLFOX4) showed one complete response and two partial responses in 13 evaluable patients. 69 A recent report of a phase I trial showed that a combination treatment with oblimersen sodium and irinotecan for metastatic colorectal cancer was well tolerated in the recommended phase II trial. 70 Patients were treated with escalating doses of oblimersen sodium administered by continuous intravenous infusion and irinotecan. Febrile neutropenia and diarrhea limited the escalation of oblimersen sodium and irinotecan. Other toxicities included nausea, vomiting, fever and fatigue. Steady-state plasma concentrations were achieved within 48 h of beginning oblimersen sodium treatment and the agent was undetectable 24 h after the discontinuation of the infusion. Another phase I trial for 16 advanced pancreatic cancers with oblimersen sodium/gemcitabine was reported. 71 These phase I trials showed the safety and limited toxicity of oblimersen sodium used in combination with standard treatment, and proceeded to phase II trials. In another phase I study for advanced Bcl-2-positive breast cancer in which continuous infusion and intermittent administration with G3139 and weekly docetaxel were compared, objective tumor response was observed in two of 22 enrolled patients. 25 G3139 in combination with standard-dose weekly docetaxel was well tolerated. The shortened and intermittent G3139 infusion had less cumulative toxicities and still allowed for a similar total G3139 delivery as the longer infusion. In addition, in a phase I study for hormone refractory prostate cancer (HPRC) with oblimersen sodium and docetaxel, prostatespecific antigen responses were observed in seven of 12 taxane-naive patients. 24 The absence of severe toxicities at this recommended dose, evidence of Bcl-2 inhibition in peripheral blood mononuclear cells (PBMCs) and tumor tissues, and encouraging antitumor activity in HPRC patients warrant further clinical evaluation of this combination. Further, in a recent phase II trial for HRPC with docetaxel and oblimersen sodium, prostatespecific antigen responses were observed in 14 of 27 (52%) patients, whereas four of 12 (33%) patients with bidimensionally measurable disease had objective responses. 72 The following results were obtained in another phase II study of oblimersen sodium and oxaliplatin and paclitaxel in patients with advanced NSCLC: overall objective response rate for all 38 patients was 34.2%, median overall survival time was 9.2 months and median progression-free survival time was 4.3 months. The regimen was well tolerated, and demonstrated Effects of antisense Bcl-2 on multiple roles of Bcl-2 R Kim et al activity in patients with advanced NSCLC. 73 In other solid tumors, a phase I/II trial for advanced and incurable hepatocellular carcinoma with oblimersen sodium and doxorubicin is in progress.
Clinical relevance as a proof of principle for targeting therapy. The conceptual basis for the therapeutic use of AS Bcl-2 is in targeting Bcl-2 mRNA, thereby enhancing the chemotherapeutic drug-induced apoptotic cell death.
As an evidence for this, the assessment of downregulation of Bcl-2 is an important marker for predicting the therapeutic effect in combination treatment. In fact, previous studies indicated that treatment with AS Bcl-2 decreased Bcl-2 mRNA and/or protein levels up to 75% in different malignancies. 23, 24, 32, 34 Others however have cited the fact that although downregulation of Bcl-2 was not observed, growth was inhibited 40 or that Bcl-2 expression in diagnostic tumor specimens was not predictive of Figure 4 Antisense and nonantisense effects of AS Bcl-2 ODNs on multiple roles of Bcl-2 in cancer chemotherapy. AS Bcl-2 enhances apoptotic cell death through the downregulation of Bcl-2 protein in the mitochondria-dependent apoptosis pathway. AS Bcl-2 also enhances autophagic cell death in the Beclin 1-dependent autophagic pathway. The CpG-motif in the AS Bcl-2 stimulates Th1-polarized immune response, which is mediated by pDCs and B cells through TLR9, connecting to T-cell activation. Other effects of AS Bcl-2 targeting Bcl-2 in iMCs and VEGF in endothelial cells may be involved in the inhibition of immune evasion and tumor angiogenesis, and which can contribute to the growth inhibition of cancer cells. Effects of antisense Bcl-2 on multiple roles of Bcl-2 R Kim et al response to this therapy. 24 In some of these reports, the assessment of Bcl-2 mRNA was more sensitive and reliable than the protein level. 23, 34 Also, the downregulation of Bcl-2 in PBMCs can be used as a surrogate marker to assess the effect of AS Bcl-2. 24, [27] [28] [29] 70, 72 Despite the differential downregulation of Bcl-2 in tumor cells and PBMCs following the treatment with AS Bcl-2, the intracellular and steady-state levels of plasma concentrations of AS Bcl-2 were increased in the responders than in the nonresponders. 72 Although the reason for the differential effect of AS Bcl-2 on downregulation of Bcl-2 is not clear, it can be speculated to be dependent on the types of cancers. Also, it is conceivable that other AS Bcl-2-induced cytotoxic actions through antisense and nonantisense effects are contributing to the increased chemotherapeutic effects in combination with AS Bcl-2. It is reasonable that even though AS Bcl-2 was initially targeted to Bcl-2, the antitumor effect can be exerted by other cytotoxic actions in the multiple roles of Bcl-2. Thus, it is unlikely that the downregulation of Bcl-2 in tumor cells and PBMCs is the only marker to predict therapeutic effect of AS Bcl-2 in various types of cancers.
Nevertheless, given that Bcl-2 serves as a key inhibitor of apoptosis that blocks the release of cytochrome c, it is conceivable that downregulation of Bcl-2 in tumors is an important factor in determining sensitivity to an anticancer drug. Several established anti-multiple myeloma agents such as dexamethasone and thalidomide inhibit Bcl-2 through NF-kB. 74 The treatment with dexamethasone or thalidomide downregulated Bcl-2, upregulated Bax expression, induced the release of mitochondrial cytochrome c into cytoplasm and activated caspase-9 and caspase-3. The increase in Bax and the decrease in Bcl-2 protein levels shift the balance of Bcl-2/Bax toward apoptosis. Bax induces pore formation in the mitochondrial membrane and ultimately facilitates the release of cytochrome c into the cytoplasm. 75 The combination treatment with AS Bcl-2 and dexamethasone and thalidomide downregulated Bcl-2, resulting in activation of the mitochondria-dependent apoptosis pathway for enhancement of chemotherapeutic effect in a syngergistic proapoptotic effect for myeloma cells. 34 Indeed, AS Bcl-2 has sensitized myeloma cells to dexamethasone and thalidomide. Another study had also shown that AS Bcl-2 could overcome resistance and restored sensitivity to vincristine, doxorubicin and dexamethasone chemotherapy in refractory myeloma patients. 76 The other case of a combination treatment with AS Bcl-2 and oxaliplatin and paclitaxel for NSCLC showed enhanced chemotherapeutic effects in the same way with activation of mitochondria-dependent apoptosis pathway by downregulation of Bcl-2. In addition, paclitaxel phosphorylates Bcl-2, resulting in inactivation of its antiapoptotic function that sensitizes tumor cells to the treatment. 77 The expected survival benefit in the combination with AS Bcl-2 needs to be demonstrated in randomized phase III study.
Concluding remarks
Several molecular targeting agents are being integrated into cancer chemotherapy for enhancing chemotherapeutic effects. The assessment of the success of any combination of molecular targeting agent and anticancer drug depends not only on the molecular mechanism that enhances the anticancer drug-induced cell death, but also on how the molecular targeting agent affects the growth inhibition of cancer cells. Both these factors can be involved in the modulation of immune evasion and angiogenesis in the tumor microenvironment. Targeting molecules should be critical for tumor proliferation, as they are involved in multiple roles in inhibiting tumor progression and metastasis. As a strategy for inhibiting Bcl-2, several nonantisense effects need to be considered for the explanation of the therapeutic efficacy observed in clinical trials, although the clinical relevance of AS Bcl-2 with the unique sequences of phosphorothioate oligonucleotides and its induced antitumor effect still remain to be determined. The antisense effect of AS Bcl-2 should be Effects of antisense Bcl-2 on multiple roles of Bcl-2 R Kim et al exerted by downregulation of Bcl-2 in target tumor cells. In point of fact, however, this simplistic statement encompasses a multitude of interactions that need to be tested for tumor response in combination treatment with an anticancer drug. These include nonantisense effect of immunostimulation, and the potential indirect effects of AS Bcl-2 ODNs or a direct antisense effect, as well as the antisense effect for other target cells that play a role in the inhibition of tumor growth. Further translational research efforts will be required to determine the mechanisms and efficacy of AS Bcl-2 in cancer chemotherapy.
